Form 10-Q Imprimis Pharmaceuticals For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Imprimis Pharma (IMMY) Misses Q1 EPS by 16c
May 12, 2016 4:56 PM EDTImprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of ($0.43), $0.16 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $3.24 million.
For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.
... More